DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Retrovir I.V. (Zidovudine Intravenous) - Published Studies


Retrovir I.V. Related Published Studies

Well-designed clinical trials related to Retrovir I.V. (Zidovudine Intravenous)

The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. [2006.09.11]

Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group. [2000.03.31]

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. [1999.03]

Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). [1998.08.15]

Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. [1995.09]

Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. [1995.03]

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. [1994.11.03]

Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. [1992.12]

Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. [1991.11.20]

Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. [1991.11]

Recombinant human erythropoietin for patients with AIDS treated with zidovudine. [1990.05.24]

Well-designed clinical trials possibly related to Retrovir I.V. (Zidovudine Intravenous)

Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. [2010.07]

Progression of HIV disease among women following delivery. [2003.08.15]

Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. [2000.07]

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. [1999.06.05]

Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. [1998.05.07]

A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. [1998]

Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. [1997.03]

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. [1996.03]

Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. [1995.02.14]

Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. [1994.06]

The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. [1994.02]

Prophylactic therapy with OKT3 does not affect donor specific reactivity of peripheral blood lymphocytes from heart transplant recipients. [1994]

Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. [1993.10]

Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients. [1991]

HIV-related thrombocytopenia. [1990]

Other research related to Retrovir I.V. (Zidovudine Intravenous)

Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug. [2011.06.06]

Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. [2010.05]

Self-assembled drug delivery systems. Part 5: self-assemblies of a bolaamphiphilic prodrug containing dual zidovudine. [2010.02.15]

Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. [2010.02]

Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine. [2009.10.20]

In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. [2009.08]

Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. [2008.07]

Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy. [2008.02.01]

Rapid and simple liquid chromatography tandem mass spectrometry method for the quantification of zidovudine in rat plasma. [2008.01]

Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. [2007.10]

Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. [2005.11]

[Antiretroviral therapy and pregnancy] [2005.01]

Simultaneous determination of zidovudine and lamivudine from rat tissues by liquid chromatography/tandem mass spectrometry. [2005]

Pharmacokinetics of zidovudine in cats. [2004.06]

Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1. [2004.03]

Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. [2004.01]

Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation. [2004.01]

Treatment of HIV infection in pregnant women: antiretroviral management options. [2004]

Factors associated with vertical HIV transmission during two different time periods: the impact of zidovudine use on clinical practice at a Brazilian reference centre. [2003.12]

Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. [2003.11.01]

Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats. [2003.03]

Pharmacokinetics and tolerance of zidovudine in preterm infants. [2003.01]

[Cytomegalovirus retinitis after highly active antiretroviral therapy: a case report] [2002.09]

Pharmacokinetics of amino acid phosphoramidate monoesters of zidovudine in rats. [2002.05]

[Prevention of vertical transmission of HIV-1 in Mallorca, Spain. Impact of antiretroviral therapy from 1995 to 2000] [2002.03.23]

Pharmacokinetics of zidovudine following intravenous bolus administration of a novel niosome preparation devoid of cholesterol. [2001.11]

Effects of intrapartum zidovudine therapy on fetal heart rate parameters in women with human immunodeficiency virus infection. [2001.11]

Human immunodeficiency virus infection in pregnant women, transmission and zidovudine therapy. [2001.07]

Intrapartum zidovudine infusion alone failed to reduce both maternal HIV-1 viral load and HIV-1 infection in infant. [2001.05]

Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study. [2001.03]

Antiretroviral treatments used among adults with HIV infection in Europe. [2001.02]

An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. [2000.12.22]

Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? [2000.12]

Antiretroviral pharmacology in pregnant women and their newborns. [2000.11]

HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. [2000.02.01]

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. [2000.01.28]

The impact of zidovudine on dementia-free survival in a population of HIV-positive men and women on antiretroviral therapy. [2000.01]

Effect of immediate neonatal zidovudine on prevention of vertical transmission of human immunodeficiency virus type 1. [2000]

Resolution of HIV-associated nephrotic syndrome with highly active antiretroviral therapy delivered by gastrostomy tube. [1999.12]

Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. [1999.12]

Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy. [1999.02]

Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. [1998.11]

Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices. [1998.10.01]

Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. [1998.10]

Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance and response related factors. [1998.09]

Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection. [1998.08]

In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. [1998.04]

Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. [1998.02]

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. [1997.11.08]

Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. [1997.07.01]

Fetal cardiorespiratory and neurobehavioral response to zidovudine (AZT) in the baboon. [1997.07]

Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. [1997.06]

Failures of zidovudine postexposure prophylaxis. [1997.05.19]

Effect of zidovudine on blood composition of the pregnant and fetal baboon. [1997.05]

Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. [1997.04]

Issues on antiretroviral post exposure combination prophylaxis. [1997.01]

Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. [1996.11]

Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy. [1996.09]

Nonclinical toxicology studies with zidovudine: acute, subacute, and chronic toxicity in rodents, dogs, and monkeys. [1996.08]

Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. [1996.05]

Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. [1996.05]

[Zidovudine-resistant HIV strains in intravenous drug users and homosexual men in Amsterdam] [1996.04.27]

Zidovudine kinetics in the pregnant baboon. [1996.02.01]

Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). [1995.12]

Effects of gender, pregnancy, and anesthesia on the pharmacokinetics of zidovudine in rats. [1995.11]

Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. [1995.07]

Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. [1995.02.01]

Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. [1995.01]

Zidovudine as an immunomodulatory agent. [1995]

Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. [1995]

Quantitative relationships between zidovudine exposure and efficacy and toxicity. [1994.08]

A cohort study of drug users' compliance with zidovudine treatment. [1994.05.23]

A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. [1994.04]

Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. [1994.03]

In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. [1994.02]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017